Related Experiment Videos
Newer antithrombotic strategies in the initial management of non-ST-segment elevation acute coronary syndromes
1Department of Pharmacy Practice and Administration, College of Pharmacy, Rutgers University, Piscataway, NJ, USA. smathis@sbhcs.com
Insights
New antithrombotic agents offer options for non-ST-segment elevation acute coronary syndromes like unstable angina and myocardial infarction. Further research is needed to determine optimal treatment combinations for reducing mortality and serious events.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Non-ST-segment elevation acute coronary syndromes (NSTE-ACS), including unstable angina and non-Q-wave myocardial infarction (MI), represent a significant clinical challenge.
- Current management strategies involve a range of antithrombotic agents, but optimal therapeutic approaches remain under investigation.
Purpose of the Study:
- To review the current role of available antithrombotic agents in the management of NSTE-ACS.
- To provide recommendations based on existing clinical data for unstable angina and non-Q-wave MI.
Main Methods:
- A comprehensive review of English-language clinical studies, position statements, and review articles.
- Focus on prospective clinical studies specifically addressing the management of NSTE-ACS, unstable angina, and non-Q-wave MI.
Main Results:
- Several antithrombotic agents (e.g., dalteparin, enoxaparin, lepirudin, clopidogrel, abciximab) are available for NSTE-ACS treatment.
- The optimal combination of agents and procedural strategies to minimize mortality and serious events has not yet been definitively determined.
- Pathophysiology, diagnostic criteria, and risk stratification for NSTE-ACS are reviewed in the context of available pharmacotherapies.
Conclusions:
- A growing number of therapeutic options exist for unstable angina and non-Q-wave MI.
- Treatment decisions are often influenced by ST-segment elevation status, despite limited prospective evidence for optimal resource utilization.
- Further research is needed to identify specific patient populations who will derive the most benefit from newly available antithrombotic therapies.
Objective:
To review the place in therapy of currently available antithrombotic agents in the non-ST-segment elevation acute coronary syndromes, that is, unstable angina and non-Q-wave myocardial infarction (MI). Recommendations are made based on currently available data.
Data Source:
English-language clinical studies, position statements, and review articles pertaining to the management of unstable angina and non-Q-wave MI with currently available products.
Study Selection:
Selection of prospective clinical studies was limited to those focusing on the management of the non-ST-segment elevation acute coronary syndromes, unstable angina, and non-Q-wave MI.
Data Synthesis:
It has yet to be determined which combination of agents (dalteparin, enoxaparin, lepirudin, clopidogrel, ticlopidine, abciximab, eptifibatide, tirofiban) and procedural strategies most significantly reduces mortality and serious events in these patients. The relevant pathophysiology, diagnostic criteria, and risk-stratifying procedures are reviewed in context with information from clinical studies regarding currently available agents for the management of non-ST-segment elevation acute coronary syndromes.
Conclusions:
A large number of new therapeutic classes and agents are available for the treatment of unstable angina and non-Q-wave MI. Although the diagnoses of unstable angina or non-Q-wave MI identify risk, treatment decisions are often based on the presence or absence of ST-segment elevations. Limited prospective evidence delineates the proper utilization of resources to best manage these patients. Efforts should be aimed at identifying particular patients who will best benefit from recently available therapies.